You are here

Vitamin D May Lower Blood Pressure in African-Americans

Researchers report ‘modest but significant’ gains (Mar. 13)

Hypertension — a risk factor for heart attacks, heart failure, and stroke — is 40% more common in African-Americans than in other American ethnic groups. In a new study from Brigham and Women’s Hospital in Boston, Mass., researchers have shown that vitamin D supplementation may help African-Americans lower their blood pressure. The findings were published online in the March 13 edition of Hypertension.

“This study may explain and help treat an important public health disparity,” said lead author John Forman, MD. “More research is needed, but these data may indicate that vitamin D supplementation lowers blood pressure in African-Americans.”

The researchers divided 250 African-American adults into four groups. Three of the groups received a 3-month regimen of daily vitamin D supplementation at various doses ranging between 1,000 and 4,000 units. The fourth group received placebo.

The participants in the placebo group saw their systolic blood pressure (SBP) rise, but the participants in the supplementation groups had their SBP decrease by one to four points, with those who received the highest dose benefiting the most.

“The gains were modest, but significant,” Forman said. “If further research supports our finding, widespread use of vitamin D supplementation in African-Americans could have significant public health benefits.”

Source: Brigham and Women’s Hospital; March 13, 2013.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function